Faculty profile

Harold Atkins

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Ottawa

Harold Atkins

Associate Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
26 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

541

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Antimicrobial Resistance Biomarker C.Difficile Infection Chimeric Antigen Receptor T-Cell Therapy Feasibility Hematopoietic Stem Cell Transplantation Microbiome Pilot

Latest papers

Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.
Clinical and experimental dermatology · 2026
Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.
Transplantation and cellular therapy · 2026
Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.
Transplantation and cellular therapy · 2026

All 67 publications

Latest funding

Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial
CIHR · 2025 · Principal investigator
$100,000
Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)
CIHR · 2025 · Co-investigator
$1,216,351
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Co-investigator
$3,216,843

All 10 grants and awards

67 publications.

Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.

Gulliver WP, Perlmutter JW, Gulliver SR, Tiplica GS, Lynde CW, Gniadecki R, Atkins H, Griffiths CEM, Lwin SM

Clinical and experimental dermatology2026

DOI: 10.1093/ced/llag301 PMID: 42462170

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.

Abduallah Y, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Thyagu S, Nampoothiri RV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.09.001 PMID: 42700928

Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.

Koo E, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Thyagu S, Vasudevan Nampoothiri R

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.01.036 PMID: 41690552

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Masurekar AN, Burkett KM, Rahgozar A, Walter RB, Othus M, Abrol K, Mortezaagha P, Thyagu S, Nampoothiri RV, Kennah M, Kekre N, Giguere P, Abduallah Y, Atkins H, Cieniak C, Berardi P, Ramsay T, Mallick R, Carrier M, Bredeson C, Allan D

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.12.996 PMID: 41482160

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.

Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Massey J, Sutton I, Withers B, Burman J, Torkildsen Ø, Bø L, Lehmann AK, Havrdova EK, Krasulova E, Trneny M, Kozak T, Macdonell R, Brown JWL, Coles A, van der Walt A, Butzkueven H, Van Wijmeersch B, Lechner-Scott J, Barnett M, Laureys G, Willekens B, Buzzard K, Skibina O, Di Gregorio M, Hodgkinson S, Ozakbas S, Meca-Lallana JE, Alroughani R, Prevost J, Foschi M, Surcinelli A, Neri S, Eichau S, McCombe P, John N, Cárdenas-Robledo S, Oh J, Sanchez-Menoyo JL, Patti F, Gerlach O, Blanco Y, Grammond P, Sharrack B, Snowden JA

Brain : a journal of neurology2026

DOI: 10.1093/brain/awaf286 PMID: 40755195

Outcome of two siblings with late-onset Krabbe disease following allogeneic hematopoietic stem cell transplantation: And review of literature.

Almudhry M, Prasad C, Tay KY, Rupar CA, Atkins H, Prasad AN

Molecular genetics and metabolism reports2025

DOI: 10.1016/j.ymgmr.2025.101242 PMID: 40727947

Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.

Monaghan M, Duong A, Abrol K, Doan T, Cieniak C, Atkins H, Kekre N, Masurekar A, Vasudevan Nampoothiri R, Thyagu S, Bredeson CN, Kennah M, Allan DS

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32090483 PMID: 41002553

Infectious complications after autologous hematopoietic stem cell transplantation for patients with an autoimmune indication: A protocol for a systematic review and meta-analysis.

Wagner CS, Lithopoulos A, Shorr R, Atkins H

Infectious diseases now2025Senior author

DOI: 10.1016/j.idnow.2025.105050 PMID: 40043807

Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Dhir V, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Vasudevan Nampoothiri R

European journal of haematology2025

DOI: 10.1111/ejh.14380 PMID: 39757868

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.

Lalu MM, Igweokpala S, Kekre N, Jeffers MS, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Giguere P, Sabri E, Sobh M, Fergusson DA

Transfusion medicine reviews2025

DOI: 10.1016/j.tmrv.2025.150897 PMID: 40280037

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Antimicrobial Resistance Dear Professor Atkins, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Profile data last refreshed on September 26, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Harold Atkins

Research

Latest papers

Latest funding

Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.

Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.

Outcome of two siblings with late-onset Krabbe disease following allogeneic hematopoietic stem cell transplantation: And review of literature.

Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.

Infectious complications after autologous hematopoietic stem cell transplantation for patients with an autoimmune indication: A protocol for a systematic review and meta-analysis.

Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.

Frequent collaborators

Natasha Kekre

David Allan

Christopher Bredeson

Kednapa Thavorn

Justin Presseau

Lothar Huebsch

Michael Kennah

Mitchell Sabloff

Brian Hutton

Terry Hawrysh

Doug Coyle

Brian Lichty

Jean-Simon Diallo

Jason Tay

Kevin Hay

Mark Freedman

Arleigh McCurdy

Stephen Juvet

Marjorie Brand

Marc Carrier

Dean Fergusson

Andrzej Chruscinski

Mads Daugaard

Leda Raptis

Derek Jonker

Antonio Giulivi

Robert Smith

Kevin Song

Aleksandra Paliga

Dawn Maze

Markus Selzner

Yan Yuan